

Jun Ren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/190750/publications.pdf>

Version: 2024-02-01

40
papers

762
citations

567281

15
h-index

552781

26
g-index

47
all docs

47
docs citations

47
times ranked

1167
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. <i>Science Translational Medicine</i> , 2021, 13, eabb6981.	12.4	84
2	Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2017, 23, 5066-5073.	7.0	62
3	Elevated level of peripheral CD8+CD28 ⁺ T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1123-1130.	4.2	54
4	MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2. <i>European Review for Medical and Pharmacological Sciences</i> , 2017, 21, 87-94.	0.7	46
5	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 1494-1504.	7.0	45
6	Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies. <i>Oncologist</i> , 2015, 20, 773-779.	3.7	44
7	Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. <i>Clinical and Translational Oncology</i> , 2013, 15, 780-788.	2.4	38
8	Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 323-331.	2.2	34
9	Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged ≥ 45). <i>Clinical and Translational Oncology</i> , 2016, 18, 82-87.	2.4	34
10	Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). <i>Clinical and Translational Oncology</i> , 2019, 21, 721-728.	2.4	32
11	DC-CIK as a widely applicable cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 601-607.	3.1	28
12	Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1197-1203.	2.5	23
13	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. <i>OncImmunology</i> , 2017, 6, e1264563.	4.6	23
14	Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. <i>International Journal of Hyperthermia</i> , 2019, 36, 74-82.	2.5	21
15	Circulating CD8 + CD28 ⁺ suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. <i>Cytotherapy</i> , 2018, 20, 126-133.	0.7	20
16	Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. <i>Pain</i> , 2020, 161, 127-134.	4.2	15
17	Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. <i>OncImmunology</i> , 2021, 10, 1976953.	4.6	13
18	Regional Variation in Identified Cancer Care Needs of Early-career Oncologists in China, India, and Pakistan. <i>Oncologist</i> , 2015, 20, 532-538.	3.7	12

#	ARTICLE	IF	CITATIONS
19	Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A meta-analysis. <i>Gene</i> , 2018, 651, 94-99.	2.2	12
20	DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 240-249.	1.8	11
21	Quantitative proteome analysis of colorectal cancer-related differential proteins. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 233-241.	2.5	10
22	Interaction between DISC1 and CHL1 in regulation of neurite outgrowth. <i>Brain Research</i> , 2016, 1648, 290-297.	2.2	9
23	Continuous DC-CIK Infusions Restore CD8+Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2419-2423.	1.2	9
24	The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. <i>Scientific Reports</i> , 2015, 5, 16775.	3.3	8
25	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 365-372.	2.3	8
26	Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. <i>Immunotherapy</i> , 2019, 11, 953-966.	2.0	8
27	Functional CD3+CD8+PD1 ^{hi} T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. <i>Clinical Breast Cancer</i> , 2019, 19, e617-e623.	2.4	8
28	Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines. <i>Oncology Reports</i> , 2016, 36, 1243-1250.	2.6	7
29	Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients. <i>Molecular and Clinical Oncology</i> , 2017, 7, 903-910.	1.0	7
30	Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 505-511.	2.1	5
31	Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 5717-5724.	1.8	4
32	Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 914-922.	0.6	4
33	Structure-based design of peptides against HER2 with cytotoxicity on colon cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2017, 45, 649-654.	2.8	3
34	Inhibition of ZERO-BK by PKC is involved in carbachol-induced enhancement of rat colon smooth muscle motility. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13312.	3.0	3
35	Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 479-490.	0.8	3
36	Expression of Lymphocyte-Activation Gene 3 (LAG-3) Immune Checkpoint Receptor Identifies a Tumor-Reactive T Cell Population in the Peripheral Blood of Patients with Colorectal Cancer. <i>Medical Science Monitor</i> , 2019, 25, 3495-3502.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy. American Journal of Cancer Research, 2021, 11, 1709-1718.	1.4	1
38	Decrease of peripheral blood CD8+/CD28-suppressor T cell followed by dendritic cells immunomodulation among metastatic breast cancer patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2010, 22, 310-315.	2.2	0
39	Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites. American Journal of Translational Research (discontinued), 2020, 12, 3940-3952.	0.0	0
40	Infiltration of metastatic lymph nodes with PD-1 T cells is associated with improved disease-free and overall survival in resected N NSCLC. American Journal of Cancer Research, 2020, 10, 4435-4449.	1.4	0